CliffBio
small molecule

ALVAIZ

ELTROMBOPAG CHOLINE

Loss of exclusivityNovember 2038latest FDA-listed patent expiry
CompanyTeva →See this company's full patent-cliff portfolio

Drug detail

Brand nameALVAIZ
Active ingredientELTROMBOPAG CHOLINE
StrengthEQ 54MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2023
Marketing statusRX

Listed patents

PatentExpiresType
11072586November 2038substance, product

More from Teva

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ALVAIZ patent cliff — loss of exclusivity November 2038 | CliffBio